Overall BIOX gets a fundamental rating of 3 out of 10. We evaluated BIOX against 83 industry peers in the Chemicals industry. BIOX has a bad profitability rating. Also its financial health evaluation is rather negative. BIOX has a decent growth rate and is not valued too expensively.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

BIOX had negative earnings in the past year.
BIOX had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: BIOX reported negative net income in multiple years.
In multiple years BIOX reported negative operating cash flow during the last 5 years.

1.2 Ratios

BIOX has a Return On Assets of -7.67%. This is in the lower half of the industry: BIOX underperforms 78.31% of its industry peers.
BIOX has a worse Return On Equity (-21.79%) than 74.70% of its industry peers.
BIOX has a Return On Invested Capital of 0.61%. This is in the lower half of the industry: BIOX underperforms 77.11% of its industry peers.

		Industry Rank	Sector Rank
ROA	-7.67%
ROE	-21.79%
ROIC	0.61%

ROA(3y)-1.49%

ROA(5y)-1.52%

ROE(3y)-4.41%

ROE(5y)-5.81%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Operating Margin of BIOX (1.27%) is worse than 75.90% of its industry peers.
Looking at the Gross Margin, with a value of 40.62%, BIOX belongs to the top of the industry, outperforming 84.34% of the companies in the same industry.
BIOX's Gross Margin has declined in the last couple of years.

		Industry Rank	Sector Rank
OM	1.27%
PM (TTM)	N/A
GM	40.62%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y2.17%

GM growth 5Y-3.14%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BIOX is destroying value.
Compared to 1 year ago, BIOX has more shares outstanding
BIOX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for BIOX is higher compared to a year ago.

2.2 Solvency

BIOX has a debt to FCF ratio of 5.58. This is a neutral value as BIOX would need 5.58 years to pay back of all of its debts.
The Debt to FCF ratio of BIOX (5.58) is better than 75.90% of its industry peers.
A Debt/Equity ratio of 0.26 indicates that BIOX is not too dependend on debt financing.
BIOX has a Debt to Equity ratio of 0.26. This is in the better half of the industry: BIOX outperforms 79.52% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.26
Debt/FCF	5.58
Altman-Z	N/A

ROIC/WACC0.09

WACC6.9%

2.3 Liquidity

A Current Ratio of 0.94 indicates that BIOX may have some problems paying its short term obligations.
The Current ratio of BIOX (0.94) is worse than 91.57% of its industry peers.
BIOX has a Quick Ratio of 0.94. This is a bad value and indicates that BIOX is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.65, BIOX is not doing good in the industry: 90.36% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	0.94
Quick Ratio	0.65

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for BIOX have decreased strongly by -2230.77% in the last year.
The Revenue for BIOX has decreased by -27.90% in the past year. This is quite bad
Measured over the past years, BIOX shows a quite strong growth in Revenue. The Revenue has been growing by 14.10% on average per year.

EPS 1Y (TTM)-2230.77%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-33.33%

Revenue 1Y (TTM)-27.9%

Revenue growth 3Y0.5%

Revenue growth 5Y14.1%

Sales Q2Q%-16.52%

3.2 Future

Based on estimates for the next years, BIOX will show a very strong growth in Earnings Per Share. The EPS will grow by 26.67% on average per year.
Based on estimates for the next years, BIOX will show a quite strong growth in Revenue. The Revenue will grow by 11.87% on average per year.

EPS Next Y63.07%

EPS Next 2Y51.42%

EPS Next 3Y39.47%

EPS Next 5Y26.67%

Revenue Next Year-13.86%

Revenue Next 2Y6.62%

Revenue Next 3Y11.13%

Revenue Next 5Y11.87%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BIOX. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 4.82, the valuation of BIOX can be described as very cheap.
Based on the Price/Forward Earnings ratio, BIOX is valued cheaper than 98.80% of the companies in the same industry.
BIOX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.83.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	4.82

4.2 Price Multiples

BIOX's Enterprise Value to EBITDA ratio is in line with the industry average.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BIOX indicates a rather cheap valuation: BIOX is cheaper than 98.80% of the companies listed in the same industry.

		Industry Rank	Sector Rank
P/FCF	1.55
EV/EBITDA	11.76

4.3 Compensation for Growth

BIOX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BIOX's earnings are expected to grow with 39.47% in the coming years. This may justify a more expensive valuation.